Your browser doesn't support javascript.
loading
Universal subunit vaccine protects against multiple SARS-CoV-2 variants and SARS-CoV.
Wang, Gang; Verma, Abhishek K; Shi, Juan; Guan, Xiaoqing; Meyerholz, David K; Bu, Fan; Wen, Wei; Liu, Bin; Li, Fang; Perlman, Stanley; Du, Lanying.
Affiliation
  • Wang G; Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
  • Verma AK; Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
  • Shi J; Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
  • Guan X; Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA.
  • Meyerholz DK; Department of Pathology, University of Iowa, Iowa City, IA, USA.
  • Bu F; Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA.
  • Wen W; Center for Coronavirus Research, University of Minnesota, Minneapolis, MN, USA.
  • Liu B; Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA.
  • Li F; Center for Coronavirus Research, University of Minnesota, Minneapolis, MN, USA.
  • Perlman S; Hormel Institute, University of Minnesota, Austin, MN, USA. liu00794@umn.edu.
  • Du L; Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN, USA. lifang@umn.edu.
NPJ Vaccines ; 9(1): 133, 2024 Jul 25.
Article in En | MEDLINE | ID: mdl-39054338
ABSTRACT
Although Omicron RBD of SARS-CoV-2 accumulates many mutations, the backbone region (truncated RBD) of spike protein is highly conserved. Here, we designed several subunit vaccines by keeping the conserved spike backbone region of SARS-CoV-2 Omicron BA.1 subvariant (S-6P-no-RBD), or inserting the RBD of Delta variant (S-6P-Delta-RBD), Omicron (BA.5) variant (S-6P-BA5-RBD), or ancestral SARS-CoV-2 (S-6P-WT-RBD) to the above backbone construct, and evaluated their ability to induce immune responses and cross-protective efficacy against various SARS-CoV-2 variants and SARS-CoV. Among the four subunit vaccines, S-6P-Delta-RBD protein elicited broad and potent neutralizing antibodies against all SARS-CoV-2 variants tested, including Alpha, Beta, Gamma, and Delta variants, the BA.1, BA.2, BA.2.75, BA.4.6, and BA.5 Omicron subvariants, and the ancestral strain of SARS-CoV-2. This vaccine prevented infection and replication of SARS-CoV-2 Omicron, and completely protected immunized mice against lethal challenge with the SARS-CoV-2 Delta variant and SARS-CoV. Sera from S-6P-Delta-RBD-immunized mice protected naive mice against challenge with the Delta variant, with significantly reduced viral titers and without pathological effects. Protection correlated positively with the serum neutralizing antibody titer. Overall, the designed vaccine has potential for development as a universal COVID-19 vaccine and/or a pan-sarbecovirus subunit vaccine that will prevent current and future outbreaks caused by SARS-CoV-2 variants and SARS-related CoVs.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Vaccines Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: NPJ Vaccines Year: 2024 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido